PTC Therapeutics Stock Plummets 4.43 Despite 72.8% Trading Volume Surge to $270M Ranks 444th in Market Activity Amid Key Drug Approvals and Financial Moves

On August 7, 2025, PTC Therapeutics (PTCT) closed with a 4.43% decline, despite a 72.8% surge in trading volume to $0.27 billion, ranking 444th in market activity. The stock’s performance followed key corporate updates and financial disclosures.

PTC announced the European Commission and FDA approvals of Sephience™ (sepiapterin) for all phenylketonuria (PKU) subtypes and age groups, marking a strategic milestone. A global launch is underway, with early access programs in the U.S., Germany, and other regions. The company also entered a $225 million upfront agreement to assume future sales obligations for Sephience, reducing financial exposure tied to prior shareholders.

Second-quarter revenue totaled $179 million, driven by $96 million in Duchenne muscular dystrophy (DMD) franchise sales, including $59 million from Translarna™ and $36 million from Emflaza®. Royalty income from Roche’s Evrysdi® sales reached $57.6 million. However, GAAP net loss widened to $64.8 million compared to $99.2 million in 2024, reflecting elevated R&D and SG&A expenses. PTC maintains a robust cash balance of $1.99 billion as of June 30, 2025.

The strategy of purchasing the top 500 stocks by daily trading volume and holding for one day achieved a 166.71% return from 2022 to the present, outperforming the benchmark by 137.53%. This highlights the role of liquidity concentration in short-term stock performance, particularly in volatile markets.